Pegaspargase CAS NO 130167-69-0 Inquire about Pegaspargase

Tecoland supplies Pegaspargase bulk active pharmaceutical ingredient (API) to the pharmaceutical industry. Our Pegaspargase is manufactured by cGMP compliant facility. Welcome to contact us for further details including current DMF status for the product and up to date regulatory status of the manufacturing facility. We look forward to assisting you with your research and development projects.
What is Pegaspargase?

Pegaspargas, trade name Oncaspar, is a modified enzyme used as an antineoplastic agent. It is a form of L-asparaginase, which has undergone PEGylation.

It is used in the treatment of acute lymphoblastic leukemia.

What is the mechanism of action?

Pegaspargase, more effective than asparaginase, converts asparagine to aspartic acid and ammonia. It facilitates production of oxaloacetate which is needed for general cellular metabolism. Some malignant cells lose the ability to produce asparagine and so the loss of exogenous sources of asparagine leads to cell death.

How to dose Pegaspargase?

The recommended dose of pegaspargase is 2,500 IU/m2 intramuscularly (IM) or intravenously (IV). Oncaspar® pegaspargase should be administered no more frequently than every 14 days.

What are the side effects?
  • severe pain in your upper stomach spreading to your back, nausea and vomiting, fast heart rate;
  • sudden numbness or weakness, especially on one side of the body;
  • sudden headache, confusion, problems with vision, speech, or balance;
  • pain or swelling in one or both legs;
  • fever, chills, body aches, flu.

Keep Pegaspargase refrigerated at 2 degrees C to 8 degrees C (36degrees F to 46 degrees F).


Information on this page is provided for general information purposes. You should not make a clinical treatment decision based on information contained in this page without consulting other references including the package insert of the drug, textbooks and where relevant, expert opinion. We cannot be held responsible for any errors you make in administering drugs mentioned on this page, nor for use of any erroneous information contained on this page.